Fosun Pays $18M for China Rights to Novel Parkinson's Disease Drug

January 10, 2018 -- Fosun Pharma acquired China rights to market a novel treatment for Parkinson's disease from Portugal's Bial in an $18 million agreement. BIAL developed Ongentys^® (opicapone) as a once-daily adjunctive therapy to levodopa/DOPA decarboxylase inhibitors. It was approved in the EU in 2016. Wanbang Biopharma, a Fosun Pharma subsidiary, will commercialize the drug in China, paying $3 million upfront and up to $15 million in milestones.